SEC Comment Letter for Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259) (OTLC) — Nov 10, 2010

Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259)
Date: Nov. 10, 2010 · CIK: 0000908259 · Accession: 0000000000-10-067332

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 000-21990

Date

November 10, 2010

Author

Not clearly detected

Form

UPLOAD

Company

Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259)

Letter

November 10, 2010 James B. Murphy Vice President and Chief Financial Officer OXiGENE, Inc. 701 Gateway Boulevard, Suite 210 South San Francisco, CA 94080

Re: OXiGENE, Inc. Preliminary Proxy Statement on Form PRE14A Filed November 2, 2010 File No. 000-21990

Dear Mr. Murphy: We have completed our review of your fili ng and do not have any further comments at this time. Sincerely,

Jeffrey Riedler Assistant Director cc: Asya S. Alexandrovich Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Center Boston, MA 02111

Show Raw Text

November 10, 2010
 James B. Murphy Vice President and Chief Financial Officer OXiGENE, Inc. 701 Gateway Boulevard, Suite 210
South San Francisco, CA 94080

Re: OXiGENE, Inc.
 Preliminary Proxy Statement on Form PRE14A
Filed November 2, 2010 File No. 000-21990

Dear Mr. Murphy:
We have completed our review of your fili ng and do not have any further comments at
this time.
Sincerely,

Jeffrey Riedler Assistant Director
 cc: Asya S. Alexandrovich  Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.  One Financial Center  Boston, MA 02111

SecProbe.io